Abstract
Glucosamine products have been used extensively for the management of pain in osteoarthritis. This paper reviews the most recent clinical and experimental studies regarding its efficacy and safety. Although clinical trials include methodologic flaws and publication bias, glucosamine is likely an effective therapy for the symptomatic management of osteoarthritis. In turn, definite proof for chondromodulating effect requires well-conducted clinical trials. In North America, glucosamine is an over-the-counter dietary supplement and preparations made by different manufacturers may vary. There is also a need to standardize this therapy and allow practitioners to give patients suitable advice. An ongoing long-term clinical trial in the US will possibly permit to investigate the clinical relevance of these results and give appropriate recommendations.
Similar content being viewed by others
References and Recommended Reading
American College of Rheumatology Subcommittee on Osteoarthritis Guidelines: recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000, 43:1905–1915.
Pendleton A, Arden N, Dougados M, et al.: EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000, 59:936–944.
Kelly GS: The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. Alt Med Rev 1998, 3:27–39.
van der Kraan PM, de Vries BJ, Vitters EL, et al.: Inhibition of glycosaminoglycan synthesis in anatomically intact rat patellar cartilage by paracetamol-induced serum sulfate depletion. Biochem Pharmacol 1988, 37:3683–3690.
van der Kraan PM, Vitters EL, de Vries BJ, van der Berg WB: High susceptibility of human articular cartilage glycosaminoglycan synthesis to changes in inorganic sulfate availability. J Orthop Res 1990, 8:565–571.
Setnikar I, Giachetti C, Zanolo G: Pharmacokinetics of glucosamine in the dog and in the man. Arzneimittelforschun 1863, 36:729–733.
Setnikar I, Palumbo R, Canali S, Zanolo G: Pharmacokinetics of glucosamine in man. Arzneimittelforschung 1993, 43:1109–1113.
Setnikar I, Rovati LC: Absorption, distribution, metabolism and excretion of glucosamine sulphate: a review. Arzneimittelforschung 2001, 51:699–725.
Adebowale A, Du J, Liang Z, Leslie JL, Eddington ND: The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm Drug Disp 2002, 23:217–225.
Aghazadeh-Habashi A, Sattari S, Pasutto F, Jamali F: High performance liquid chromatographic determination of glucosamine in rat plasma. J Pharm Pharm Sci 2002, 5:176–180.
Barclay TS, Tsourounis C, McCart GM: Glucosamine. Ann Pharmacother 1998, 32:602–603.
Largo R, Alvarez-Soria MA, Diez-Ortego I, et al.: Glucosamine inhibits IL-1beta-induced NF-kappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2003, 11:290–298. Glucosamine inhibits the synthesis of proinflammatory mediators in human osteoarthritic chondrocytes.
Bassleer C, Rovati L, Franchimont P: Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage 1998, 6:427–434.
Setnikar I, Cereda R, Pacini MA, Revel L: Antireactive properties of glucosamine sulfate. Arzneimittelforschung 1991, 41:157–161.
Setnikar I, Pacini MA, Revel L: Anti-arthritic effects of glucosamine sulfate studied in animal models. Arzneimittelforschung 1991, 41:542–545.
Sandy JD, Thompson V, Verscharen C: Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 1998, 335:59–66.
Shikhman AR, Kuhn K, Alaaeddine N, Lotz M: N-acetylglucosamine prevents in IL-beta-mediated activation of human chondrocytes. J Immunol 2001, 166:5155–5160.
Oegema TR, Deloria LB, Sandy JD, Hart DA: Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis Rheum 2002, 46:2495–2503.
Noyszewski EA, Wroblewski K, Dodge GR, et al.: Preferential incorporation of glucosamine into the galactosamine moieties of chondroitin sulfates in articular cartilage explants. Arthritis Rheum 2001, 44:1089–1095.
Mroz PJ, Silbert JE: Effects of [3H]glucosamine concentration on [3H]chondroitin sulfate formation by cultured chondrocytes. Biochem J 2003, in press.
Lippiello L: Glucosamine and chondroitin sulfate: biological response modifiers of chondrocytes under simulated conditions of joint stress. Osteoarthritis Cartilage 2003, 11:335–342. These observations suggest that, by enhancing the “protective” metabolic response of chondrocytes to stress, glucosamine and chodroitin sulfate may improve its ability for repair and regeneration.
Dodge GR, Jimenez SA: Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage 2003, 11:424–432. Glucosamine may have a beneficial effect in the prevention of articular cartilage loss in some patients with OA.
Tiku ML: Role of lipid oxidative stress in osteoarthritis: glucosamine inhibits advanced lipoxidation reaction and scavenges reactive carbonyl intermediates [abstract]. Ann Rheum Dis 2003, 62(suppl):S376.
Towheed TE, Anastassiades TP, Shea B, et al.: Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2001, 1:CD002946.
Houpt JB, McMillan R, Wein C, Paget-Dellio SD: Effect of glucosamine hydrochloride in the treatment of pain osteoarthritis of the knee. J Rheumatol 1999, 26:2294–2297.
Chard JA, Tallon D, Dieppe PA: Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint. Ann Rheum Dis 2000, 59:414–418.
McAlindon TE, LaValley MP, Gulin JP, Felson DT: Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and metaanalysis. JAMA 2000, 283:1469–1475.
Richy F, Bruyere O, Ethgen O, et al.: Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003, 163:1514–1522. This data-analysis suggests efficacy for glucosamine on joint space narrowing and Western Ontario and McMaster Universities Osteoarthritis Index.
Reginster JY, Deroisy R, Rovati LC, et al.: Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet 2001, 357:251–256.
Pavelka K, Gatterova J, Olejarova M, et al.: Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002, 162:2113–2123.
Mazzuca SA, Brandt KD, Lane KA, Katz BP: Knee pain reduces joint space width in conventional standing anteroposterior radiographs of osteoarthritic knees. Arthritis Rheum 2002, 46:1223–1227.
Hughes R, Carr A: A randomized, double-blind, placebocontrolled trial of glucosamine sulfate as an analgesic in osteoarthritis of the knee. Rheumatology 2002, 241:279–284. This pragmatic study does not show symptomatic effect of glucosamine sulfate.
Rindone JP, Hiller D, Collacott E, et al.: Randomized controlled trial of glucosamine for treating osteoarthritis of the knee. Wes J Med 2000, 172:91–94.
Cohen M, Wolfe R, Mai T, Lewis D: A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. J Rheumatol 2003, 30:523–528.
Tapadinhas MJ, Rivera IC, Bignamini AA: Oral glucosamine sulfate in the management of arthrosis: report on a multicenter open investigation in Portugal. Pharmatherapeutica 1982, 3:157–168.
Towheed TE: Current status of glucosamine therapy in osteoarthritis. Arthritis Rheum 2003, 49:601–604.
de Mattei M, Pellati A, Pasello M, et al.: High doses of glucosamine-HCl have detrimental effects on bovine articular cartilage explants cultured in vitro. Osteoarthritis Cartilage 2002, 10:816–825.
National Institutes of Health web site. Accessible at http://www.nih.gov.
Reginster JY, Bruyere O, Henrotin Y: New perspectives in the management of osteoarthritis structure modification: facts or fantasy? J Rheumatol 2003, 30(suppl):14–20.
Russell AS, Aghazadeh-Habashi A, Jamali F: Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol 2002, 29:2407–2409.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zerkak, D., Dougados, M. The use of glucosamine therapy in osteoarthritis. Current Science Inc 8, 507–511 (2004). https://doi.org/10.1007/s11916-004-0074-0
Issue Date:
DOI: https://doi.org/10.1007/s11916-004-0074-0